未登录

C

Carmen Ayuso

university of barcelona

H指数:43

被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update

用于预后预测和治疗建议的BCLC策略: 2025更新

Journal of Hepatology

IF33

2025-10-270

PRE

Evidence and choice: The BCLC vision for tailoring clinical decision-making

JOURNAL OF HEPATOLOGY

IF33

2024-10-010

PRE

MRI USING GADOXETIC ACID IN THE WORK-UP OF LIVER NODULES NOT CONCLUSIVELY BENIGN IN BUDD-CHIARI SYNDROME. A PROSPECTIVE LONG-TERM FOLLOW-UP

IF9.1

2023-08-180

OAAI

Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules

JOURNAL OF HEPATOLOGY

IF33

2022-04-0121

PRE

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

用于预后预测和治疗建议的BCLC策略: 2022更新

JOURNAL OF HEPATOLOGY

IF33

2022-03-012.2K

OAAI

Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival

JOURNAL OF HEPATOLOGY

IF33

2021-11-0113

PREAI

Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

索拉非尼早期腹泻作为考虑向二线药物早期迁移的标志

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL

IF6.7

2021-07-061

OAAI

Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules ≤2 cm in cirrhosis

LIVER INTERNATIONAL

IF5.2

2019-05-2819

PREAI

Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines (vol 101, pg 72, 2018)

EUROPEAN JOURNAL OF RADIOLOGY

IF3.3

2019-03-014

PREAI

Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals

JOURNAL OF HEPATOLOGY

IF33

2018-04-010

PREAI

Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism

JOURNAL OF HEPATOLOGY

IF33

2018-04-014

PREAI

Prospective evaluation of gadoxetic-acid MR for the non-invasive diagnosis of hepatocellular carcinoma in newly detected nodules <=2 cm in cirrhotic patients

JOURNAL OF HEPATOLOGY

IF33

2018-04-011

PREAI

Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)

LIVER TRANSPLANTATION

IF3.9

2018-02-2354

OAAI

Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence

JOURNAL OF HEPATOLOGY

IF33

2017-01-010

PREAI

COMPLETE RESPONSE UNDER SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA IS ASSOCIATED TO DEVELOPMENT OF DERMATOLOGY ADVERSE EVENTS

JOURNAL OF HEPATOLOGY

IF33

2016-01-010

PREAI

Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US

IF15.2

2015-06-01111

PREAI

Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm

JOURNAL OF HEPATOLOGY

IF33

2015-01-0144

PREAI

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

早期皮肤病不良事件预测索拉非尼治疗的HCC患者的预后更好

JOURNAL OF HEPATOLOGY

IF33

2014-08-01203

PREAI

Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design

IF15.8

2013-10-29218

PRE

DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

JOURNAL OF HEPATOLOGY

IF33

2013-04-010

PREAI